Figure S1 from Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas

Abstract

CONSORT diagram of samples that underwent MSK-IMPACT sequencing and analyzed for clinical outcomes with frontline PD-1 based therapy.